![Gabriel Morris](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gabriel Morris
Direttore Finanziario/CFO presso IMMIX BIOPHARMA, INC.
Patrimonio netto: 1 M $ in data 30/06/2024
Posizioni attive di Gabriel Morris
Società | Posizione | Inizio | Fine |
---|---|---|---|
IMMIX BIOPHARMA, INC. | Direttore/Membro del Consiglio | 01/03/2021 | - |
Direttore Finanziario/CFO | 01/03/2021 | - | |
Contatto Relazioni con gli Investitori | 01/03/2021 | - | |
Alwaysraise LLC | Corporate Officer/Principal | 01/01/2020 | - |
Nexcella, Inc.
![]() Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Presidente | - | - |
Storia della carriera di Gabriel Morris
Precedenti posizioni note di Gabriel Morris
Società | Posizione | Inizio | Fine |
---|---|---|---|
Campbell & Co. LP
![]() Campbell & Co. LP Investment ManagersFinance Campbell & Co. LP provides investments management services. It is a pioneer in absolute return investment management, specializing in systematic managed futures and equity market-neutral strategies. The company provides absolute return investment strategies and global diversification in a single investment. Campbell & Co was founded in 1972 and is located in Towson, MD. | Direttore operativo | - | 03/01/2021 |
ZAP Surgical Systems, Inc.
![]() ZAP Surgical Systems, Inc. Internet Software/ServicesTechnology Services Zap Surgical Systems, Inc. operates as a gyroscopic radiosurgery platform. The company was founded by John R. Adler and is headquartered in San Carlos, CA. | Direttore Finanziario/CFO | 01/01/2019 | 01/01/2020 |
Formazione di Gabriel Morris
The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 7 |
Posizioni
Director of Finance/CFO | 2 |
Director/Board Member | 1 |
Investor Relations Contact | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Technology Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
IMMIX BIOPHARMA, INC. | Health Technology |
Aziende private | 4 |
---|---|
Alwaysraise LLC | |
ZAP Surgical Systems, Inc.
![]() ZAP Surgical Systems, Inc. Internet Software/ServicesTechnology Services Zap Surgical Systems, Inc. operates as a gyroscopic radiosurgery platform. The company was founded by John R. Adler and is headquartered in San Carlos, CA. | Technology Services |
Campbell & Co. LP
![]() Campbell & Co. LP Investment ManagersFinance Campbell & Co. LP provides investments management services. It is a pioneer in absolute return investment management, specializing in systematic managed futures and equity market-neutral strategies. The company provides absolute return investment strategies and global diversification in a single investment. Campbell & Co was founded in 1972 and is located in Towson, MD. | Finance |
Nexcella, Inc.
![]() Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
- Borsa valori
- Insiders
- Gabriel Morris
- Esperienza